Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
University of Pennsylvania
With
Merck Sharp & Dohme LLC
We propose to complete a randomized controlled trial (RCT) of 200 subjects with medication treated diabetes and evidence of poor adherence to a statin medication (\<70% medication possession ratio determined through pharmacy records; no combination meds). Study subjects will use an electronic pill bottle (GlowCap) to store their statin medication. Study subjects will identify potential Medication Adherence Partners (MAPs) who can receive information about their adherence patterns at enrollment. For the 90-day trial, subjects will be randomized to: 1) the subject's MAP receives daily notification about whether subject took statin; 2) the subject's MAP receives weekly about how often the subject took statin during previous week; 3) the subject's MAP receives notification if the subject missed \>2 consecutive daily doses of statin; and 4) usual care (GlowCaps without any notifications). The primary outcome will be the percent of statin doses taken during the study as measured by the GlowCaps. The secondary outcome will be subjects' statin medication possession ratio (MPR) during the study.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
The subject is Humana insured
The subject is an English speaking adult
Age range ≥18 years
The subject has diagnosis with diabetes for ≥12 months
The subject has an MPR \<70% to a statin medication
Subject denies side-effects to their statin medication
The subject identified a person who agreed to serve as their MAP
You may not be if
The subject is \<18 years old
The subject is considered part of a vulnerable population (is a prisoner, a cognitively impaired person, or a pregnant woman)
On statin combination medication
The subject does not identify an individual who agrees to serve as their MAP
The subject reports a clinically important side effect to the statin medication or active liver disease:
